Table 1.
Pathological impact of Mcl-1 overexpression in cancers
| Type of cancer | Pathological impact of Mcl-1 overexpression | References |
|---|---|---|
| Prostate | Resistance to therapies and apoptosis | [48, 126] |
| Breast | Resistance to therapies and apoptosis, contributes to metastasis | [42, 68] |
| Ovarian | Therapy resistance, poor prognosis | [43, 127] |
| Renal | Blocks apoptosis | [128] |
| Lung | Promotes survival and drives lung cancer progression | [14, 129] |
| Colon | Resistance to targeted therapies and apoptosis | [66, 130] |
| Pancreatic | Resistance to therapies and apoptosis | [131, 132] |
| Head and neck | Resistance to therapies, tumor progression, poor prognosis | [15, 133] |
| Melanoma | Resistance to apoptosis | [105, 134] |
| MM | Disease relapse, poor prognosis | [135, 136] |
| AML | Therapy resistance, disease relapse | [18, 137] |
| NHL | Disease progression, high-grade lymphoma | [138, 139] |
MM: multiple myeloma; AML: acute myeloid leukemia; NHL: non-Hodgkin lymphoma